Kenneth Gordon to Thalidomide
This is a "connection" page, showing publications Kenneth Gordon has written about Thalidomide.
Connection Strength
0.637
-
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024 Feb 01; 160(2):204-209.
Score: 0.237
-
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023 08; 15(11):787-797.
Score: 0.225
-
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul; 73(1):37-49.
Score: 0.131
-
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1445-1486.
Score: 0.045